Physician profile
Christopher Biggiani
NPI 1962065276
$1,383.40
in general payments reported to CMS, 2019-2025
22 companies · $876 in 2025
The $876 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $61.67 · 2024: $445 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $160.04 | 2024-2025 | Korlym |
| Novo Nordisk INC | $157.94 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $155.51 | 2024-2025 | |
| Abbott Laboratories | $141.96 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $113.38 | 2023-2025 | Repatha, Tepezza, Repatha |
| Xeris Pharmaceuticals, INC. | $109.24 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $57.73 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $56.09 | 2025 | |
| Medtronic, INC. | $55.51 | 2024-2025 | Minimed 780g |
| Lilly USA, LLC | $50.62 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Insulet Corporation | $46.42 | 2025 | Omnipod |
| Beta Bionics, INC. | $45.94 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $35.17 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $34.81 | 2024-2025 | Unithroid |
| Radius Health, INC. | $34.34 | 2025 | Tymlos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.99 | 2023 | |
| Recordati_rare_diseases_inc. | $23.87 | 2024 | Signifor Lar, Isturisa |
| Currax Pharmaceuticals LLC | $17.29 | 2025 | Contrave |
| Esperion Therapeutics, INC. | $16.78 | 2024 | Nexletol |
| Alexion Pharmaceuticals, INC. | $16.15 | 2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $15.65 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $14.97 | 2025 | Twiist |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Biggiani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.